About Blood Neoplasia

Blood Neoplasia focuses on hematologic malignancies, including leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, myeloproliferative neoplasms, minimal residual disease, and precursor conditions to neoplasia.

Blood Neoplasia provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations that focus on hematologic malignancies and associated disorders – including leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, hemophagocytic lymphohistiocytosis, myeloproliferative neoplasms, minimal residual disease, and precursor conditions. All articles undergo a rigorous peer review. They are selected based on the originality of the findings, the superior quality of the work described, the clarity of presentation, and the expected impact on patient care.

Inaugural Editor-in-Chief

Dr. Jonathan Licht – Editor-in-Chief of Blood Neoplasia – is a visionary physician-scientist who brings to the journal an extensive background in scientific publication. An accomplished author, reviewer, and editor, he has authored over 200 publications with approximately 32,000 citations, reviewed and edited hundreds of scientific publications, and served on the editorial boards of major journals in the areas of blood, blood diseases, and cancer.

Dr. Licht is poised to usher in a new era of innovation in blood cancer research. He aims to ensure that Blood Neoplasia employs novel approaches in article review and magnifies the visibility and prominence of research in the field. Dr. Licht is focused on appointing an editorial board that is diverse and multifaceted in identity, geography, and career stage. He is dedicated to maintaining an author-friendly and low-barrier submission process along with rigorous and transparent peer review.

“The increasing pace of biomedical research and submissions offers Blood Neoplasia an opportunity to capture some of the best manuscripts in the field, provide rapid publication, and efficiently disseminate the findings.”

----Jonathan Licht, MD, 2023 Vision Statement